Skip to content

A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder

A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05621538
Acronym
CNT
Enrollment
90
Registered
2022-11-18
Start date
2025-10-01
Completion date
2026-03-31
Last updated
2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder

Keywords

treatment seeking, alcohol, TMS, neurofeedback, supplemental intervention, heavy drinking, problems with drinking

Brief summary

The goal of this clinical study is to test the effectiveness of a supplemental fMRI neurofeedback and/or TMS intervention in individuals seeking treatment for Alcohol Use Disorder. After an initial visit, participants will come in once a week for four (4) weeks for an intervention session, which may or may not include TMS and MRI. Participants will be contacted for monthly follow-ups (remotely) for up to 12 months and will be asked to come in for two MRI follow-ups at 6 and 12 months.

Interventions

BEHAVIORALRealtime fMRI Neurofeedback - Active

fMRI aided reinforcement of craving regulation

DEVICETMS - Active

rTMS to right dorsolateral prefrontal cortex to reduce craving

BEHAVIORALRealtime fMRI Neurofeedback - Yoked Sham

Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation

rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
Auburn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

The PI will prospectively assign treatment groups with blind codes and so will not be blind to treatment type. Other staff, who are the individuals primarily working with the patients and who will be conducting follow-up interviews, will be blind to treatment type. It is not possible to blind the 5th condition (treatment as usual with a brief check-in).

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Age 19-65 2. Receiving treatment for Alcohol Use Disorder

Exclusion criteria

1. MRI Contraindications 1. Presence of metal in the body that would make having a 7T MRI unsafe (including facial tattoos) 2. Claustrophobia, such that individual would be unable to stay in the MRI for up to 1 hr 3. Hearing loss, including tinnitus, that might be made worse by MRI or TMS 2. TMS Contraindications 1. Has ever had a seizure, or has a family history of epilepsy 2. Taking medications or substances that lower the seizure threshold 3. Implanted devices that are in the head or rely on physiological signals 4. History of neurological disease, such as stroke or brain tumor 5. Head injury with loss of consciousness greater than 30 minutes 6. Actively withdrawing from alcohol 3. Family history of schizophrenia or presence of psychotic symptoms

Design outcomes

Primary

MeasureTime frameDescription
Change in Brain Activity during Simultaneous Sociomoral & Alcohol Cue Presentation over TimeAssessed at weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)Measured via fMRI; alcohol-cued sociomoral processing
Change in Aggression and Victimization over TimeAssessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57 (follow-ups)Revised Conflict Tactics Scales (CTS-R)
Change in Antisocial Behavior over TimeAssessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57 (follow-ups)number of self-reported contacts with the police, convictions, and other criminal behaviors
Change in Brain Activity during Alcohol Cue Presentation over TimeAssessed at weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)Measured via fMRI; standard alcohol cue reactivity
Change in Alcohol Use over TimeAssessed at weeks: 1 (baseline), 2-5 (intervention sessions, pre and post), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)Alcohol Timeline Followback (alc-TLFB)
Change in Alcohol Craving over TimeAssessed at weeks: 1 (baseline), 2-5 (intervention sessions, pre and post), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)Alcohol Craving Questionnaire (ACQ)
Change in Community Functioning over TimeAssessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)Drinker Inventory of Consequences (DrInC)
Change in Employment Status over TimeAssessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)self-reported employment status

Secondary

MeasureTime frameDescription
Change in Brain White Matter Structure over TimeWeeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)Measured via MRI; white matter diffusion
Change in Resting State Functional Connectivity over TimeWeeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)Measured via fMRI
Change in Brain Gray Matter Structure over TimeWeeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)Measured via MRI; gray matter volume

Countries

United States

Contacts

Primary ContactSCAMPI Lab
scampi@auburn.edu334-521-2807

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026